Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway(Pennington Biomedical Research Center), Eduardo Dunayevich(VistaGen Therapeutics (United States)), Raymond A Plodkowski(University of California San Diego), Ken Fujioka(Scripps Clinic), Maria Guttadauria, J. Erickson(Clinical Solutions), Dennis Dong Hwan Kim(Princess Margaret Cancer Centre), Sunder Mudaliar(University of California, San Diego)
Cited by 1,018
Related Papers
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
|Diabetes Care|2013|494
Physiological adaptations to weight loss and factors favouring weight regain
|International Journal of Obesity|2015|414